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Abstract 1 
Statins are widely prescribed inhibitors of the mevalonate pathway, acting to lower 2 
systemic cholesterol levels. The mevalonate pathway is critical for tumorigenesis and 3 
is frequently upregulated in cancer. Nonetheless, reported effects of statins on tumor 4 
progression are ambiguous, making it unclear if statins, alone or in combination, can 5 
be used for chemotherapy. Here, using advanced mass spectrometry and isotope 6 
tracing, we showed that statins only modestly affected cancer cholesterol 7 
homeostasis. Instead, they significantly reduced synthesis and levels of another 8 
downstream product, the mitochondrial electron carrier coenzyme Q, both in cultured 9 
cancer cells and tumors. This compromised oxidative phosphorylation, causing 10 
severe oxidative stress. To compensate, cancer cells upregulated antioxidant 11 
metabolic pathways, including reductive carboxylation, proline synthesis, and cystine 12 
import. Targeting cystine import with an xCT transporter-lowering MEK inhibitor, in 13 
combination with statins, caused profound tumor cell death. Thus, statin-induced 14 
ROS production in cancer cells can be exploited in a combinatorial regimen. 15 
 16 
Statement of Significance 17 
Cancer cells induce specific metabolic pathways to alleviate the increased oxidative 18 
stress caused by statin treatment, targeting one of these pathways synergizes with 19 
statins to produce a robust anti-tumor response. 20 
 21 
 22 
 23 
 24 
 25 
Introduction  1 
The mevalonate pathway plays an important role in cellular and systemic physiology, 2 
with downstream pathways contributing to the proper functioning of a diverse set of 3 
biological processes. Synthesis of mevalonate occurs by concatenating 3 acetyl-CoA 4 
molecules, followed by a reduction step by the enzyme HMG-CoA reductase. 5 
Mevalonate is then subject to further phosphorylation and decarboxylation steps, 6 
together catalyzing the production of 5-carbon isoprenoid molecules, three of which 7 
are used to synthesize a 15-carbon farnesyl pyrophosphate (FPP) molecule (Fig.1A). 8 
Isoprenoids and FPP feed into separate downstream pathways to produce a variety 9 
of biomolecules. These are (I) dolichols, which are made up of varying numbers of 10 
isoprene units and act as anchors for glycosylation structures, (II) prenyl units for 11 
protein prenylation, enabling their anchoring into membranes (1), (III)  coenzyme Q 12 
(CoQ), or ubiquinone, an essential electron carrier in the electron transport chain (2), 13 
and (IV) cholesterol. Cholesterol is arguably the best studied product of the 14 
mevalonate pathway, and is an important lipid that acts as a structural component of 15 
mammalian cell membranes and a precursor for the synthesis of steroid hormones, 16 
bile acid, and vitamin D (3).  17 
Although cholesterol contributes to a variety of important physiological 18 
processes, excess levels (hypercholesterolemia) are often observed in individuals 19 
with metabolic syndrome, and it is strongly linked to cardiovascular disease (4). This 20 
has spurred significant interest into potential pharmacological interventions, leading 21 
to the development of statins. These are a class of drugs that inhibit the rate-limiting 22 
enzyme producing mevalonate, HMG-CoA reductase (HMGCR), and are thought to 23 
exert their beneficial effect by normalizing systemic cholesterol levels. Due to their 24 
favorable efficacy and safety profiles, statins are now amongst the most widely 1 
prescribed medicines in the clinic (5).  2 
In recent years there have been many reports linking upregulated activity of 3 
the mevalonate and downstream metabolic pathways to cancer development and 4 
progression (6,7). For example, in breast cancer it was found that high HMGCR and 5 
additional mevalonate pathway gene transcript levels correlated with poor prognosis 6 
(6). Likewise, comparison of pancreatic ductal adenocarcinoma (PDAC) and normal 7 
pancreas tissue revealed strongly deregulated cholesterol metabolism (8). In 8 
addition, it was recently shown that p53 represses the mevalonate pathway and this 9 
is one mechanism by which it suppresses tumor development (9). Finally, a 10 
commonly occurring driver oncogene, Ras, is prenylated to facilitate its localization 11 
to the inside of the plasma membrane. This has been shown to co-operate with 12 
increased HMGCR levels to promote transformation (6).  13 
Despite the clear dysregulation of the mevalonate pathway in a variety of 14 
cancer types, robust evidence for a therapeutic benefit of statin treatment remains, 15 
limited to only a subset of cancer types. Statin use in combination with androgen-16 
deprivation therapy increased time to progression in prostate cancer (10). Similarly in 17 
breast cancer, statin use post diagnosis led to a reduced risk of recurrence, although 18 
the largest increase was observed when statin use was combined with angiotensin 19 
receptor blocker treatment (11). Notably, in the subset of cancers where statins do 20 
appear to be effective, this cannot merely be attributed to their effect on protein 21 
prenylation (12), indicating that other parts of the mevalonate and downstream 22 
pathways contribute to tumorigenesis and could be blocked to achieve clinical 23 
benefit.  24 
This discrepancy between upregulated activity of the mevalonate and 1 
branching pathways, and the limited clinical effect of statins in most cancer types, 2 
suggested to us that cells may be able to adapt their metabolism in response to 3 
statin treatment. Here, we performed a comprehensive stable isotope tracing study 4 
with both 13C and 2H tracers, to determine which branches of mevalonate 5 
metabolism are active in cancer cells and tumors, and how they may be affected by 6 
statin treatment. This led to the finding that biosynthesis of coenzyme Q (CoQ) is 7 
very pronounced in cultured cells and in tumors. CoQ depletion due to statin 8 
treatment causes reduced oxidative phosphorylation and significantly elevated ROS 9 
production. Cancer cells in turn boost redox-active metabolic pathways to alleviate 10 
ROS levels, with increased cystine import for glutathione production among the 11 
strongest responses. While statins on their own had modest cytostatic effects, 12 
combination with a MEK-inhibitor (AZD6244), which lowers xCT cystine transporter 13 
levels, led to synergistic induction of cancer cell death. Thus statins cause metabolic 14 
vulnerabilities, and targeting these in a combination treatment paradigm elicits 15 
powerful anti-tumor effects.  16 
 17 
Methods 18 
Cell culture 19 
KPC mouse cells originally derived from Pdx1-Cre; KrasG12D/+; Trp53R172H/+ (KPC) 20 
mice (C57BL/6J background), were kindly provided by Dr Jennifer Morton. MIA 21 
PaCa-2 PDAC cells were purchased from the American Type Culture Collection. The 22 
PC3 prostate cancer cell line was kindly provided by Dr Hing Leung. All cells were 23 
routinely passaged in Dulbecco’s Modified Eagle Medium (DMEM, Sigma) with 25 24 
mM glucose and 2 mM L-glutamine, supplemented with 5% (v/v) serum (FBS; 25 
Sigma) (base medium). Cells were split at 80% confluence and checked for 1 
mycoplasma every 6 weeks using a luciferase based Mycoalert Mycoplasma 2 
detection assay (Lonza). Cell lines were authenticated by extracting genomic DNA 3 
(Qiagen kit), carrying out Multiplex PCR using GENE PRINT 10 (Promega) and 4 
running samples on a 31/30 XL Genetic Analyzer. Cells were plated for experiments 5 
2 passages after thawing and each biological replicate was separated by one 6 
passage thereafter. 24 h prior to experiment, cells were plated in 12-well plates, to 7 
reach 80% confluency at end point.  Experiments were performed in DMEM 8 
(experiment medium) supplemented with 2% or 5% dialyzed FBS (DFBS, Sigma) 9 
and as indicated with the following nutrients: 10 mM [U13C]-glucose (Cambridge 10 
isotopes) and/or 2 mM [U13C]-glutamine (Sigma), or unlabeled glucose and 11 
glutamine at same concentrations. Simvastatin, pitavastatin and atorvastatin (all 12 
Sigma) were used at 2 μM concentration, and AZD6244 was used at 250 nM. 13 
Rescue experiments were performed using mevalonolactone (Sigma), N-acetyl 14 
cysteine (Sigma), mevalonolactone-(methyl-13C) (Sigma) or 13C9-L-Tyrosine (Sigma) 15 
in experimental quantification medium. Cell numbers were determined using a CASY 16 
Cell Counter (Roche). 17 
 18 
Cellular experiments 19 
Cells were first plated in 12-well plates in base medium for 24 h, and thereafter 20 
medium was replaced to the indicated experiment medium and cells cultured for 48 h 21 
for small molecule metabolites, CoQ and dolichol experiments, and 72 h for 22 
cholesterol experiments. Cells were cultured in experiment medium for 48 h for cell 23 
counting assays and rescue experiments.  24 
 25 
Mice 1 
Animal work was performed under Home Office license (70-8645) with ethical 2 
approval from the University of Glasgow Animal and Ethical Review board (AWERB). 3 
Mice were given access to standard diet and water ad libitum in conventional cages. 4 
All mouse work was conducted in accordance with ARRIVE guidelines. KPC mice, 5 
previously described (13), were genotyped by Transnetyx (Cordoba, TN, USA), were 6 
monitored at least 3 times per week, and put on indicated treatment when pancreatic 7 
malignancy was confirmed by abdominal palpitation. Mice were sacrificed after 7 8 
days of treatment. Adult mice of both sexes were randomly assigned to cohorts.  9 
 10 
Mouse treatment 11 
Upon pancreatic malignancy confirmation, mice were randomly assigned to cohorts. 12 
Drug treatment began on the same day as deuterated water supplementation (see 13 
below). Mice were given either a daily oral gavage of 100 µL simvastatin vehicle 14 
(0.5% methyl cellulose/5% DMSO), simvastatin (50 mg/kg in 0.5% methyl 15 
cellulose/5% DMSO) or a twice daily oral gavage of AZD6244 (25 mg/kg 0.5% 16 
HPMC + 0.1% Tween-80), or an  AZD6244 gavage along with a simvastatin gavage, 17 
for 7 days. 18 
 19 
2H2O tracing in mice 20 
Mice were fasted for 6 h prior to termination. Mice were first given an intraperitoneal 21 
bolus injection of 0.035 mL/g 0.9% NaCl 2H2O, made up using 0.9 g NaCl in 100 mL 22 
2H2O and sterile filtered. Mice were then provided with 8% 
2H2O in the drinking water 23 
for 7 days. A previously performed time-course analysis demonstrated that steady 24 
state 2H enrichment of approximately 5% of body water was achieved after 5 days, in 1 
agreement with results published by others (14). 2 
 3 
Analysis of 2H2O enrichment in body water 4 
Plasma was taken at end point and deuterium enrichment in body water was 5 
determined via deuterium acetone exchange as described (15,16).  6 
 7 
Tissue homogenization 8 
Mouse tissue samples were snap frozen and homogenized in a CryocoolerTM (OPS 9 
Diagnostics). A mass of 5-10 mg of tissue was then weighed and vortexed for 15 min 10 
at 4oC at 3000 rpm in the appropriate extraction buffer and internal standards (as 11 
described below).  12 
 13 
Cholesterol extraction and derivatization from cells, medium and tissues 14 
For cellular extracts, at the time of extraction cells were first washed 3x with1 mL 4°C 15 
PBS before 700 µL 4°C extraction buffer (1:9 v/v water: methanol) was added. Plates 16 
were incubated for 5 min at 4°C before being scraped into HPLC vials and 20 µL of 17 
lathosterol (100 ng/µL) internal standard added.  18 
For media extracts, samples were centrifuged at 16,100 g for 5 min at 4°C to 19 
remove cell debris and 500 µL supernatant vortexed for 15 min at 3000 rpm at 4°C 20 
with 500 µL 1:1 v/v chloroform: methanol and 20 µL of lathosterol (100 ng/µL, Sigma) 21 
internal standard. Samples were centrifuged at 16,100g for 5 min at 4°C, the bottom 22 
chloroform layer extracted, transferred to an HPLC vial and dried under N2. Samples 23 
were resuspended in 750 µL cold extraction buffer (1:9 v/v water: methanol). For 24 
tissue, 700 µL 4°C extraction buffer and 20 µL of lathosterol (as an internal standard) 1 
was used as detailed in tissue extraction.  2 
All samples (cell extracts, medium, tissue) were saponified by heating for 60 3 
min at 80°C with 75 µL of 10 M NaOH to obtain the total cholesterol pool. Upon 4 
cooling to room temperature, 200 µL water was added, followed by 500 µL n-5 
hexane. Vials were vortexed for 5 min at 3000 rpm, and the upper hexane layer 6 
transferred to an autosampler vial. The n-hexane extraction was repeated and 7 
samples dried under N2. Samples were reconstituted in 50 µL dry pyridine and 50 µL 8 
N-Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA, Sigma) silylation agent 9 
added. Samples were heated at 60°C for 60 min before cooling and immediate 10 
analysis by GC-MS. 11 
 12 
Dolichol and CoQ extraction 13 
At time of extraction, cells were placed on ice and washed 3 times in 1 mL cold PBS 14 
before 750 μL extraction buffer (1:1 v/v PBS: methanol) was added to cells and 15 
scraped into 1.5 mL Eppendorf tubes and 500 µL chloroform added. Similarly, for 16 
tissues following homogenization as detailed above, 750 μL extraction buffer and 17 
then 500 µL chloroform added was added to sample. For all samples, 50 µL 1 18 
mg/mL methanolic butylated hydroxytoluene (BHT, Sigma); SPLASH lipidomix 19 
internal standard mix (Avanti Polar Lipids) at 1 µL per 5 mg tissue/105 cells and 2H9-20 
CoQ10 (Sigma) at 500 ng/mL per 5 mg tissue/10
5 cells was added. Samples were 21 
centrifuged at 10,000 g for 5 min before the lower chloroform layer was extracted 22 
and dried under N2. Samples were reconstituted in 1:1 v/v methanol: chloroform at 23 
100 µL/105 cells or 0.2 mL/mg tissue and stored at -20°C until LC-MS analysis. 24 
 25 
Metabolite extraction 1 
Intracellular metabolite extraction was performed as follows: on ice, cells were 2 
washed 3x 1 mL in cold PBS before 500 μL 4°C extraction buffer (methanol, 3 
acetonitrile, and water (5:3:2) v/v) was added. After 5 min cells were scraped into 4 
Eppendorf tubes and shaken for 15 min at 3000 rpm at 4°C. Tubes were centrifuged 5 
at 16,100 g for 5 min at 4°C and the supernatants were transferred into HPLC vials. 6 
Vials were stored at -80°C prior to LC-MS analysis. 7 
Media samples were centrifuged at 16,100 g for 5 min at 4°C to remove cell 8 
debris and the supernatant vortexed for 15 min at 3000 rpm at 4°C with cold 9 
extraction buffer (methanol, acetonitrile, and water (50:30:20 v/v). Samples were 10 
centrifuged at 16,100 g for 5 min at 4°C, and the supernatants were transferred into 11 
HPLC vials. In addition, a pooled sample of supernatants was created. A series of 12 
standard curves were created with pooled samples spiked with increasing 13 
concentrations of [U13C]-labeled glucose, lactate, glutamate and glutamine, which 14 
were used to determine the concentration of glucose, lactate, glutamate and 15 
glutamine in media samples. For cystine, peak area was used for a relative 16 
concentration to be calculated.  17 
Tissues were reconstituted in extraction buffer (methanol, acetonitrile, and 18 
water, 50:30:20 v/v) at 5 mL/mg tissue. 19 
 20 
Acetone analysis by GC-MS 21 
Acetone was analyzed using an Agilent 7890B GC system coupled to a 7000 Agilent 22 
Triple Quadrupole GC-MS system, with a Phenomenex ZB-1701 column 23 
(30 m × 0.25 mm × 0.25 μm). An initial temperature of 40 oC was set to increase at 10 24 
°C/min up to 100°C, held for 0 min. The instrument was operated in split mode 1 
(220:1) in the electron impact mode, 70eV.  2 
 3 
Cholesterol analysis by GC-MS 4 
Cholesterol was analyzed using an Agilent 7890B GC system coupled to an Agilent 5 
7000 Triple Quadrupole GC-MS system which was operating in a single quadrupole 6 
mode, with a Phenomenex ZB-1701 column (30 m × 0.25 mm × 0.25 μm). An initial 7 
temperature of 200 °C was set to increase at 20 °C/min up to 280 °C, held for 9 min. 8 
The instrument was operated in splitless mode in the electron impact mode, 70eV, 9 
for quantification and 50eV for labeling experiments. Cholesterol was quantified and 10 
isotope labeling pattern analyzed using Mass Hunter B.06.00 software (Agilent). 11 
Cholesterol and lathosterol internal standard peak areas were extracted from mass-12 
to-charge ratio (m/z) 458 for both. Cholesterol was normalized to the internal 13 
standard, and a standard curve was used to quantify mg cholesterol per sample.  14 
 15 
CoQ and dolichol analysis by LC-MS 16 
LC-MS analysis was performed as described in (17). CoQ was analyzed in positive 17 
mode using spray voltage 3 kV. Full MS (scan range 300-1600 m/z) was used at 70 18 
000 resolution with 106 automatic gain control and a maximum injection time of 250 19 
ms. For CoQ quantification, XCalibur Software (Thermo) was used to analyze peak 20 
height of CoQ9, CoQ10 and 
2H9-CoQ10 internal standard. Similarly, for dolichols, peak 21 
height of dolichol-19 in dolichol internal standard mix (Avanti) was analyzed. Peak 22 
heights were normalized against both the internal standard and cell number.  23 
 24 
 25 
Metabolite analysis by LC-MS 1 
This was performed as described in (18). Peak areas were determined using Thermo 2 
TraceFinder software. Metabolites were identified by a combination of exact masses 3 
of ions and retention times. This was validated using commercial standards of all 4 
detected metabolites run on the system prior to analysis. Peak areas were 5 
normalized to cell number. 6 
 7 
Body water 2H2O enrichment calculations 8 
Acetone was quantified and isotope labeling pattern analyzed using Mass Hunter 9 
B.06.00 software (Agilent). Mass isotopologs 58 and 59 were integrated and their 10 
ratio compared to a standard curve to quantify plasma 2H2O enrichment, as 11 
described (15,16). 12 
 13 
Cholesterol, CoQ and dolichol 13C and 2H tracing calculations 14 
For both [U13C]-glucose/glutamine and 2H2O CoQ and dolichol tracing MAVEN 15 
software (19) was used. For cholesterol, Mass Hunter B.06.00 software was used. 16 
Peak area for each isotope was extracted and natural abundance isotope correction 17 
performed using an in-house generated algorithm.  18 
For 13C mass isotopolog distributions, calculation of fraction newly 19 
synthesized cholesterol, dolichol and CoQ was calculated by dividing each 20 
isotopolog by the sum of all isotopologs. Calculation of the fraction newly 21 
synthesized cholesterol, dolichol and CoQ from in vivo 2H2O experiments was 22 
performed according to Lee et al (20, 21).  23 
 24 
 25 
XF cell mito stress analysis 1 
Oxygen consumption rate was determined using an XFe96 extracellular flux analyzer 2 
(Seahorse Agilent Technologies). Mitochondrial respiratory capacity was determined 3 
using XF Cell Mito Stress Kit (Agilent Technologies). 24 h prior to analysis, cells 4 
were seeded in 5% dFBS supplemented base medium containing 10 mM glucose 5 
and 2 mM glutamine and the indicated drugs or DMSO control. 1 h prior to assay, 6 
media was replaced with Seahorse media containing 1% dFBS, 10 mM glucose and 7 
2 mM glutamine and indicated drugs/DMSO, pH 7.4. During the assay, 1 μM 8 
oligomycin A, 1 μM FCCP, and 0.5 μM rotenone/antimycin A were sequentially 9 
added. 10 
 11 
NRF2 Knock-down  12 
Cells were passaged 12 h prior to transfection with RNAiMAX (Invitrogen) and 13 
siRNA: siGENOME non-targeting control pool (Dharmacon), NRF2 (Nfe212) 14 
(Qiagen, SI01326815, SI01326822), according to the vendor’s protocol. After 48 h 15 
cells were plated and treated as described. 16 
 17 
Synergy Assay 18 
Cells were plated in 24 well plates in base media for 24 h, thereafter media was 19 
replaced with base media plus drug or control (DMSO). Simvastatin was used at: 20 
0.5, 1, 2, 4, 8 µM. AZD6244 was used at 0.25, 1, 2, 5, 10, 15, 20 µM. A combinatorial 21 
matrix of these concentrations was then tested. An Incucyte Zoom (Essen 22 
Bioscience) was used to image wells and confluency after 96 h was determined 23 
using Incucyte Zoom software (Essen Bioscience). Confluency data was normalized 24 
to the vehicle (DMSO) condition. For each drug alone, using Microsoft Excel, the 25 
confluency curve was fitted to a cubic equation. The cubic equation was then used to 1 
create a lookup table of percent inhibition vs drug concentration. The ICX for a given 2 
X was then obtained finding the X value in the percent inhibition column and 3 
retrieving the associated drug concentration. For a given X and drug concentrations 4 
D1 and D2, the drug combination index (CI) was then calculated as described by 5 
Chou-Talalay (22), using the following equation: 6 
  7 
Where DA and DB are the concentration of simvastatin and AZD6244 used in 8 
combination to achieve X % drug effect. ICX,A and ICX,B are the concentrations of 9 
simvastatin and AZD6244 as single agents to achieve the same effect. A CI of less 10 
than 1 indicates synergy.  11 
 12 
Real-time quantitative PCR 13 
RNA was extracted using the RNAeasy kit (QIAGEN) and cDNA synthesized using 14 
QuantiTect Reverse Transcription Kit (QIAGEN). SYBR Green Master Mix (Bio-Rad) 15 
was used to prepare PCR reaction mixtures containing 1 μg of cDNA. A CFX96 16 
thermal cycler (Bio-rad) was used to perform the PCR reaction. Tubulin was used as 17 
a reference gene for mouse and actin for human samples. 18 
 19 
DCFDA assay 20 
2′, 7′-Dichlorofluorescin diacetate (DCFDA) was used to measure intracellular ROS 21 
using the DCFDA Cellular ROS Detection Assay Kit (ab113851, AbCam) according 22 
to the manufacturer’s protocol. Cells were treated for 24 h in the indicated conditions 23 
prior to assay in base media containing 5% dFBS, 10 mM glucose and 2 mM 24 
glutamine and indicated drugs/DMSO with no phenol red. A Tecan SPARK plate 25 
reader with excitation/emission wavelengths filter: 490/510–570 nm was used to 1 
detect fluorescence. Average relative fluorescence of control was equated to 2 
100%, with treatment conditions calculated proportionally. Signal was background 3 
corrected and adjusted to cell number. 4 
 5 
Immunohistochemistry 6 
Immunohistochemistry of formalin-fixed paraffin-embedded tumor and benign 7 
pancreas blocks was obtained from cohort mice treated with vehicle, simvastatin or 8 
simvastatin + AZD6244. Phospho-Histone H2A.X (Ser139) (20E3) (ɣH2AX) (Cell 9 
Signalling), at 1:50 dilution, anti-8-Hydroxy-2’-deoxyguanosine (N45.1) (s-hydroxy) 10 
(AbCam) at 1:200 dilution, Caspase-3 (Cell Signaling) at 1:500 dilution primary 11 
antibodies were used. Antigens were retrieved in a PT Module (Agilent) for 25 min at 12 
98oC in PT Module 1 buffer (Thermo, UK). For Phospho-Histone H2A.X and 13 
caspase-3 endogenous peroxidase activity was blocked by incubation with 3% H2O2. 14 
This step was carried out after anti-8-Hydroxy-2’-deoxyguanosine staining, so as not 15 
to disrupt ROS. Staining was performed on a Dako Autostainer Link48 (for s-hydroxy 16 
and ɣH2AX) and a Leica Bond RX Autostainer (Caspase-3) with the primary 17 
antibody applied for 45 min at room temperature and 30 min, respectively. Sections 18 
were washed with Tris Buffered Tween (TbT) and Rabbit EnVision (Agilent, UK) was 19 
applied for 30 min, before washing with TbT and then application of Liquid DAB 20 
(Agilent, UK) for 10 min. Sections were rinsed in water on an autostainer and 21 
counterstained with Haematoxylin, nuceli blue’d, before being dehydrated and 22 
cleared through graded alcohols and xylene before application of a permanent 23 
coverslip. 24 
 25 
Results 1 
Statins only modestly affect cholesterol pools, but robustly block coenzyme Q 2 
synthesis in cancer cells 3 
Cells acquire cholesterol either through uptake of lipoproteins from the extracellular 4 
environment, or by synthesizing it de novo (23) (Fig. 1A). In pancreatic and prostate 5 
cancer, cholesterol metabolism genes in particular have been shown to be 6 
deregulated (8,24). Cholesterol synthesis itself has not been measured before in 7 
these cancer types, and therefore we explored cholesterol dynamics as well as the 8 
effect of statins.  9 
We performed a stable isotope tracing experiment with both [U13C]-glucose 10 
and [U13C]-glutamine in a cancer cell line derived from the KPC (Pdx1-Cre; 11 
KrasG12D/+; Trp53R172H/+) genetically engineered mouse model of pancreatic ductal 12 
adenocarcinoma (PDAC). In the presence of 5% (high) serum approximately 90% of 13 
the cholesterol remained unlabeled and very little 13C accumulated in the 27-carbon 14 
molecule (Fig. 1B, S1A), thus indicating minimal de novo synthesis, but robust 15 
uptake of (unlabeled) cholesterol from the medium.  As serum is a source of 16 
unlabeled cholesterol, we next lowered extracellular cholesterol by reducing serum 17 
to 2% (low) (Fig. 1B, S1A). While the fraction of unlabeled (M0) cholesterol remained 18 
substantial, the presence of heavily 13C-labeled isotopologs now demonstrated 19 
active cholesterol synthesis (Fig. 1B). Of note, we observed partially labeled 20 
molecules that contain both 12C and 13C. This is still indicative of complete de novo 21 
cholesterol synthesis, and is caused by partial labeling of the acetyl-CoA pool, which 22 
is also observed for other macro-molecules (25). Based on this labeling pattern, 23 
uptake (M0) and synthesis (M14 – M27) contributed roughly equally to the cholesterol 24 
pool (Fig. S1A). A similar observation was made in the human PDAC cell line MIA-25 
PaCa2 (Fig. S1B-D). These results demonstrate that cancer cells preferentially take 1 
up cholesterol from their extracellular environment, but can maintain cholesterol 2 
homeostasis by inducing de novo synthesis when extracellular availability is limited. 3 
This homeostasis is maintained during statin treatment (Fig. S1D); Simvastatin 4 
treatment in low serum conditions potently abrogated de novo cholesterol synthesis, 5 
but cells were still able adapt to maintain their cholesterol pool size by increasing 6 
cholesterol uptake (Fig. S1D-F). 7 
By modulating serum availability during treatment of PDAC cell lines with 8 
simvastatin, we observed potent anti-proliferative effects in both high and low serum 9 
conditions (Fig. 1C, S1G). This finding was recapitulated with pitavastatin and 10 
atorvastatin, in KPC, MIA-PaCa2 and a human prostate cancer cell line, PC3 (Fig. 11 
S1G). As cholesterol synthesis is active in low serum but inactive in high serum, this 12 
suggests the anti-proliferative effect of statins is not mediated through inhibition of 13 
cholesterol metabolism. We therefore started exploring other branches of the 14 
mevalonate pathway (Fig. 1A). Using liquid chromatography – mass spectrometry 15 
(LC-MS)-based lipidomics, we were able to directly measure both dolichols and 16 
coenzyme Q (CoQ), also known as ubiquinone. Dolichols are composed of multiple 17 
concatenated 5-carbon isoprenoid units and function to ‘anchor’ glycosylation 18 
structures in membranes (26). CoQ is comprised of a benzoquinone ring derived 19 
from tyrosine, attached to a 9 (mouse, CoQ9) or 10 (human, CoQ10) isoprenoid-unit 20 
tail (Fig. 1D) (27). It functions as an electron carrier in the electron transport chain 21 
(ETC), and hence supports oxidative phosphorylation (2).  22 
Analysis of dolichol labeling from [U13C]-glucose and [U13C]-glutamine 23 
revealed relatively little 13C-incorporation, and hence a low rate of de novo synthesis 24 
(Fig. S1H). This contrasted with CoQ, which showed abundant 13C-incorporation as 25 
evidenced by the formation of a multitude of 13C-labeled isotopologs (Fig. 1E). We 1 
confirmed that providing 13C-labeled mevalonolactone, a routinely used cell 2 
permeable mevalonate analog that is rapidly converted upon entry into the cell, and 3 
tyrosine, also led to labeled CoQ (Fig. S1I-K). In all cell lines tested, statin treatment 4 
significantly reduced both de novo synthesis of CoQ and consequently CoQ pool 5 
size (Fig. 1F, 1G, S1L, M).  It took 24 hours for statins to have a clear effect on CoQ 6 
levels, and this effect could be rescued using mevalonolactone (Fig. S1N). Together, 7 
these results demonstrate that, in contrast to cholesterol, CoQ is actively produced 8 
by cancer cells, and that both synthesis and pool size are reduced upon statin 9 
treatment. 10 
 11 
Decreased CoQ levels cause impaired oxidative phosphorylation and a 12 
compensatory shift toward glycolysis 13 
Succinate dehydrogenase (SDH), or complex II, participates both in the TCA cycle 14 
and the electron transport chain. It couples the oxidation of succinate with the 15 
reduction of CoQ (28). To establish whether diminished CoQ levels post statin 16 
treatment inhibited SDH activity, we determined the levels of its direct substrate 17 
succinate (Fig. 2A, S2A). Indeed, statin treatment caused significantly higher 18 
succinate levels, suggesting inhibition of SDH activity. We next asked if reduced 19 
SDH activity due to statin-mediated CoQ depletion more broadly impacted central 20 
carbon metabolism. We therefore measured oxygen consumption rate (OCR) after 21 
24 hours of statin treatment, as CoQ depletion is strongest at this time (Fig. S1N). 22 
Simvastatin, pitavastatin and atorvastatin all reduced both basal and maximal 23 
respiration (Fig. 2B, S2B). Thus, reduced CoQ levels lowered oxidative 24 
phosphorylation (OXPHOS). Cells can compensate for loss of energy production 25 
from the TCA cycle by increasing glycolysis. In accordance with this, we observed 1 
increased glucose uptake and lactate secretion (Fig. 2C, S2C). Of note, OXPHOS 2 
was restored upon mevalonolactone supplementation (Fig. S2D). Thus, cells switch 3 
to glycolysis to compensate for loss of OXPHOS-mediated ATP production due to 4 
statin-mediated CoQ depletion.  5 
 6 
Statin-induced reduction in CoQ levels causes elevated ROS and activation of 7 
antioxidant metabolic pathways 8 
Mitochondrial metabolism is intimately linked with ROS maintenance, and 9 
dysfunctional oxidative phosphorylation, as we observed with statin treatment (Fig. 10 
2), can be a principal cause for excessive ROS generation (29).  Additionally, the 11 
reduced form of CoQ, also known as ubiquinol, may have antioxidant functions in 12 
cells beyond oxidative phosphorylation (30). We next mined our metabolomics 13 
dataset to evaluate if oxidative stress occurs in statin treated cells.  This revealed a 14 
striking shift in the ratio between oxidized and reduced glutathione towards the more 15 
oxidized form (Fig. 3A, S3A). Thus, it appears that oxidative stress is indeed a major 16 
consequence of statin treatment in cancer cells.  17 
In recent years, multiple metabolic adaptations have been shown to have the 18 
ability to regulate redox balance (31). These adaptations include (I) the reductive 19 
formation of citrate from glutamine for shuttling NADPH into the mitochondria (32), 20 
(II) increased cellular cystine import for glutathione production (33), and (III) the 21 
synthesis of proline as an electron sink and ROS scavenger (34) (Fig 3B). Each of 22 
these pathways uses glutamine or derived metabolites as a substrate, and we 23 
therefore asked if glutamine uptake by statin treated cells was changed. Our analysis 24 
revealed a robust, roughly two-fold or higher increase in the rate by which glutamine 25 
is taken up by statin treated cells, compared to untreated cells (Fig. 3C, S3B). While 1 
glutamate release also increased, it did not fully account for the increased uptake of 2 
glutamine, suggesting that statin treatment increases the rate by which glutamine-3 
derived carbon feeds into downstream pathways.  4 
We next investigated the effect of statin treatment on the activity of the 5 
aforementioned pathways that use glutamine as a substrate. Reductive citrate 6 
synthesis can be monitored using the M+5 isotopolog after feeding the cells [U13C]-7 
glutamine. In concordance with a change in central carbon metabolism and a 8 
potential role in redox management, the M+5 isotopolog and hence reductive 9 
carboxylation was robustly induced upon statin treatment (Fig. 3D, S3C). In addition, 10 
glutamine-derived glutamate can be exchanged with cystine via the 11 
cystine/glutamate antiporter SLC7A11/Slc7a11 (xCT) for glutathione production. 12 
Consistent with this pathway being active, glutamate secretion increased upon statin 13 
treatment, as did cystine uptake and intracellular cystine levels (Fig 3E, 3F, S3D, 14 
S3E). The transcript levels of xCT transporter also increased (Fig. 3G, S3F).  15 
 Finally, proline synthesis by pyrroline-5-carboxylate reductase (PYCR) from 16 
glutamine can also help regulate redox balance by regenerating NAD+ which in turn 17 
may promote TCA cycling (35). Accordingly, we found that statin treatment robustly 18 
increased proline from glutamine (Fig. 3H, S3G).  PYCR1/Pycr1 transcript levels 19 
were also elevated (Fig. 3I, S3H). Proline itself can act as a ROS scavenger, 20 
reacting with hydroxyl radicals to form hydroxyproline (34,36). We indeed observed 21 
intracellular hydroxyproline levels to be significantly increased upon statin treatment 22 
(Fig. 3J, S3I). Thus, proline synthesis from glutamine helps to regenerate NAD+ and 23 
facilitate ROS scavenging.  24 
We next asked if the effects of statin-induced redox stress could be alleviated 1 
by mevalonolactone supplementation (Fig. 3G, 3I, S3A, S3C, S3E-I). Indeed, cell 2 
proliferation was rescued by mevalonolactone supplementation, as well as by the 3 
antioxidant N-acetyl cysteine addition (Fig. S3J). Of note, direct CoQ 4 
supplementation did not rescue cell growth, but this could have been caused by the 5 
precipitation of CoQ in the culture medium, and we were unable to confirm uptake or 6 
use by the cells. Nevertheless, the ability of N-acetyl cysteine to rescue the effect of 7 
simvastatin is further evidence that the depletion of CoQ and resulting oxidative 8 
stress is an important mechanism of statin-induced cell death. Overall, our results 9 
indicate that treating cancer cells with statins leads to pronounced oxidative stress 10 
and cells compensate by activating redox-induced metabolic pathways that mitigate 11 
ROS damage.  12 
 13 
Statin treatment decreases CoQ synthesis and causes oxidative stress, in vivo 14 
We next evaluated mevalonate pathway activity in vivo using 2H2O tracing, which 15 
enables persistent labeling of macromolecules (37,38). Pdx1-Cre; KrasG12D/+; 16 
Trp53R172H/+ (KPC) mice were administered a 0.035 mL/g mouse weight 2H2O bolus 17 
to mice with palpable tumors, followed by exposure to 8% 2H2O in drinking water for 18 
7 days, which consistently led to approximately 5% deuterium enrichment in plasma 19 
(Fig. S4A).  20 
 We assessed 2H-enrichment in cholesterol. A fractional enrichment of 21 
approximately 0.45 was observed in both liver and plasma of KPC mice (Fig. S4B, 22 
S4C). In healthy pancreas and tumors, the fractional enrichment of cholesterol was 23 
comparable to what was observed in plasma (Fig. S4D), suggesting that the de novo 24 
synthesis of cholesterol in tumors is minimal, as tumors actively take it up from the 25 
bloodstream.  Statin treatment had no significant impact on cholesterol labeling (Fig. 1 
S4C) or levels, which is consistent with reports that statins do not affect circulating 2 
blood cholesterol in mice, in contrast to in humans (39,40). Analysis of in vivo 3 
dolichol labeling revealed a similar labeling pattern to cholesterol, with labeling in 4 
tumors somewhat lower than in plasma, suggestive of minimal synthesis in the 5 
tumor, with no observable effect of simvastatin (Fig. S4E, S4F). 6 
 We next proceeded with analysis of CoQ. Notably, CoQ 2H labeling in the 7 
small intestine was very high (fractional enrichment ~0.9), presumably due to the 8 
extremely rapid turnover of the epithelium (Fig. S4G).   Fractional enrichment of 9 
circulating CoQ was strikingly similar to cholesterol (Fig. S4H). In contrast, while 10 
CoQ labeling in healthy pancreas was lower than circulating CoQ, the inverse was 11 
true in KPC PDAC tumors, where enrichment was significantly higher (Fig. 4A). As 12 
the enrichment is higher than circulating CoQ, this indicates active synthesis in the 13 
tumor. This was significantly reduced upon statin treatment (Fig. 4A). Notably, 14 
plasma CoQ9 levels were not significantly altered by statin treatment, indicating a 15 
tumor specific effect (Fig. S4I), which appears in contrast to studies in healthy 16 
humans (41). Nevertheless, we conclude that PDAC tumors actively synthesize 17 
CoQ, and this synthesis is reduced by statin treatment.   18 
We next wanted to investigate whether simvastatin treated tumors also had 19 
elevated ROS levels. Indeed, our immunohistochemistry demonstrated elevated 20 
oxidative damage, as there was significantly greater staining of ɣH2AX in the 21 
simvastatin treated cohort (Fig. 4B). We used 8-hydroxyguanosine as a DNA 22 
damage marker (42), and found significantly more stained cells in the simvastatin 23 
treated cohort than vehicle treated (Fig. S4J). Consistent with the metabolic 24 
compensation observed in vitro, we found that metabolic compensation to mitigate 25 
oxidative stress occurred in the PDAC tumors. Specifically, we observed a significant 1 
increase in xCT (Slc7a11) transcript levels (Fig. 4C). Thus, simvastatin treatment 2 
leads to increased tumor ROS and tumors compensate by attempting to elevate 3 
glutathione production via xCT upregulation.  4 
  5 
Combined statin and MEK inhibitor treatment synergize to accumulate ROS 6 
and cause apoptosis 7 
Our findings revealed that statins reduce CoQ levels, causing oxidative stress, and 8 
metabolic compensation occurs to mitigate the effects of ROS damage. We next 9 
asked if disrupting these metabolic adaptations, together with statin treatment, would 10 
synergize to induce tumor cell death. The most pronounced metabolic adaptation we 11 
observed in vivo was upregulation of the xCT transporter (Fig. 4C). It was previously 12 
shown that the MEK inhibitor AZD6244 can promote ROS via NRF2 activation (43). 13 
In line with this, we found simvastatin treatment increased NRF2 transcript levels, 14 
whilst AZD6244 treatment reduced NRF2 transcript levels, as expected (Fig. S5A). 15 
As xCT is a NRF2 target (44) and NRF2 itself is regulated by MEK (45), we sought to 16 
determine if the ROS promoting effect of AZD6244 was through lowered expression 17 
of xCT. Indeed, AZD6244 was able to reduce xCT transporter levels in cultured 18 
cancer cells (Fig. 5A). We further validated this by testing MEK targets and found 19 
them to be reduced (Fig. S5B). Specifically, our previous results showed simvastatin 20 
elevates xCT mRNA levels, but in combination with AZD6244 this was prevented 21 
and the expression even reduced below the vehicle condition (Fig. 5A). This resulted 22 
in reduced cystine uptake (Fig. S5C), indicating that cells were not able to 23 
compensate for the elevated ROS from simvastatin treatment through increased 24 
cystine uptake for glutathione synthesis. In accordance, ROS levels were 25 
significantly increased using the combination treatment (Fig. 5B). There was also a 1 
trend towards increased glutathione oxidation after combination treatment (Fig. 2 
S5D). Overall the combination treatment exacerbates ROS levels. Importantly, 3 
proliferation was substantially reduced upon combination treatment and NRF2 4 
knock-down (Fig. 5C, S5E, S5F). NRF2 KD reduced NRF2 target transcript levels, 5 
and most notably xCT levels (Fig. S5G). Combined these results suggest AZD6244 6 
may be synergizing with simvastatin. 7 
 To explore the potential synergy of AZD6244 and simvastatin further, the 8 
effect upon cell proliferation of the two drugs as single agents and in combination 9 
was analyzed (see Fig. S5H, S5I for example graphs). Using a matrix of all drug 10 
concentration combinations, the combination index (CI), as described by Chou-11 
Talalay, was calculated (Fig. S5J, S5K). This demonstrated that the two drugs 12 
synergized at all except the very highest concentrations. 13 
 These results obtained in vitro led us to investigate the potency of a dual 14 
treatment of AZD6244 and simvastatin in vivo. We found the combination treatment 15 
reduced in vivo xCT transcript levels to well below the simvastatin treatment alone, 16 
and was comparable to the AZD6244 single-arm treatment (Fig. 5D). This shows 17 
AZD6244 is able to counter the elevated xCT levels induced by statin treatment in 18 
the tumor setting (Fig. 5E). Strikingly, our immunohistochemistry revealed caspase-3 19 
induction and associated apoptotic body numbers were significantly higher in the 20 
combination treatment compared to vehicle, AZD6244 or simvastatin alone (Fig. 5F, 21 
5G). Combined, these results indicate that a combined treatment with statin and a 22 
MEK inhibitor may be an effective cancer treatment paradigm.  23 
 24 
 25 
Discussion 1 
Our rationale for studying the mevalonate and downstream pathways in cancer was 2 
two-fold. First, while the mevalonate pathway is known to be upregulated in a 3 
number of different cancer types (6,8,10), and to be critical for tumorigenesis (9), 4 
what downstream products are synthesized and how they contribute to 5 
tumorigenesis, thus far remained largely unexplored. Second, despite the 6 
importance of the mevalonate pathway in cancer, the chemotherapeutic potential of 7 
the ubiquitously prescribed statins, either as a single agent or in a combination 8 
strategy, remained uncertain. We combined both GC-MS and LC-MS modalities with 9 
innovative stable isotope tracing approaches to determine the metabolic activity of 10 
this branch of metabolism, as well as the compensatory mechanisms that occur 11 
upon pharmacological inhibition. 12 
 It is well established that statins lower circulating cholesterol levels in humans, 13 
yet few studies have looked at cholesterol metabolism directly in cancers (8,46). 14 
Using tracers, we directly measured cholesterol metabolism, both in vitro and in vivo, 15 
to reveal that cancer cells preferentially take up cholesterol, rather than synthesizing 16 
it. Cholesterol uptake occurs via the LDL receptor and its increased expression has 17 
been reported in a variety of tumor types, including pancreatic cancer (8). 18 
Although our labeling studies clearly demonstrated that cholesterol synthesis 19 
is minimal in tumor cells, statin treatment still elicited a robust anti-proliferative 20 
response. Through further exploration using an innovative combination of stable 21 
isotope tracing and lipidomics, we discovered that CoQ is actively synthesized by 22 
cancer cells. This contrasted with the synthesis of dolichols, which showed 23 
substantially less pronounced labeling.  The principal function of CoQ is to act as an 24 
electron carrier in the electron transport chain (ETC), to facilitate mitochondrial 25 
respiration. Apart from distinct oncogenic mutations and deletions in TCA cycle 1 
enzymes (47), mitochondrial metabolism is typically active in tumor cells and an 2 
important source for both energy and building blocks for macro-molecules (48). In 3 
fact, multiple recent reports demonstrated heightened glucose oxidation in tumors 4 
(49,50), stressing the importance of mitochondrial metabolism in cancer. 5 
Statin-mediated CoQ depletion causes severe oxidative stress, which is likely 6 
caused by the disruption in mitochondrial metabolism. A few reports have previously 7 
postulated a link between statins, reduced CoQ levels, and increased ROS in other 8 
cell types, and this has been suggested as a cause for statin-induced myopathy 9 
(51,52). However, the published data supporting this was circumstantial. We now 10 
establish this link in unprecedented detail and show it also occurs in cancer cells. 11 
Furthermore, we made the novel observation that statin-mediated CoQ depletion 12 
leads to the compensatory induction of multiple metabolic pathways, with each 13 
having a unique anti-oxidant role. Particularly pronounced in both in vitro and in vivo 14 
settings was the upregulated expression of the xCT transporter. This has previously 15 
been shown to occur in response to oxidative stress by helping cells to obtain cystine 16 
needed for glutathione production (53).  Of note, the statin mediated effect on ROS 17 
through CoQ is distinctly different from recent reports on squalene, which 18 
accumulates in some cancers and has an antioxidant function (54,55). 19 
Our study highlights the capability of statins to inhibit CoQ synthesis. 20 
However, we recognize that this may not be the sole chemotherapeutic effect of 21 
statins. Multiple elegant reports have highlighted the pronounced effect of statins on 22 
protein prenylation, a post-translational modification that occurs on prominent 23 
oncoproteins, including members of the RAS family (56,57). Recent evidence, 24 
however, clearly demonstrated that the anticancer effects of statins is not due to 25 
reduced RAS protein prenylation (12). Therefore, other statin-induced alterations, 1 
including the pronounced ROS production due to CoQ loss, contribute to its 2 
chemotherapeutic potential. 3 
 Statins, extensively prescribed for cardiovascular disease, have been widely 4 
evaluated for their effects on tumor development and progression, yet their clinical 5 
effect is variable (58–60). A phase II clinical trial of simvastatin and gemcitabine in 6 
PDAC patients found no clinical benefit to combining the statin with the only 7 
chemotherapy currently available for pancreatic cancer patients (61). Similarly for 8 
prostate cancer, a recent randomized double blind trial found no significant 9 
difference between atorvastatin and placebo (62). We explored statins in both 10 
pancreatic and prostate cancer cell lines, as well as an in vivo genetically engineered 11 
mouse model of PDAC. Both in vitro and in vivo simvastatin reduced CoQ synthesis 12 
significantly and tumors exhibited elevated ROS levels and xCT transcript levels. 13 
This led us to target the compensatory xCT upregulation using the MEK inhibitor 14 
AZD6244 and we found this dual combination with simvastatin induced apoptosis in 15 
the tumor. Our findings are directly relevant to unearthing a potential therapy for 16 
these cancers by hitting the cancers metabolic ROS compensatory mechanism to 17 
statin action.  18 
We urgently need better treatments to target aggressive cancers such as 19 
PDAC, for which therapeutic options are currently very limited. We have used two 20 
FDA approved drugs and demonstrated their synergy and potential as a 21 
combinatorial cancer therapy.  22 
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 25 
Figure 1. The cytostatic effect of statins is mediated through a decrease in 1 
coenzyme Q  2 
(A) Schematic overview of the mevalonate pathway. (B) Cholesterol labeling 3 
distribution in KPC (Pdx1-Cre; KrasG12D/+; Trp53R172H/+) cells incubated with [U13C]-4 
glucose and [U13C]-glutamine fed for 72 h in either high serum (5% dFBS) or low 5 
serum (2% dFBS). Data has been corrected for 13C natural abundance. The orange 6 
carbons on the cholesterol molecules represent 12C and the purple carbons 7 
represent 13C. (C) Effect of simvastatin (Simva) on cell proliferation in high and low 8 
serum. KPC and MIA-PaCa2 cells were treated with simvastatin in high (5%) or low 9 
(2%) serum for 48 h. Numbers are relative to vehicle (DMSO) treated control. (D) 10 
Schematic of CoQ (Coenzyme Q) biosynthesis using 5C (5 carbon) isoprene units 11 
from the mevalonate pathway. (E) CoQ labeling pattern from [U13C]-glucose and 12 
[U13C]-glutamine fed to KPC cells for 48 h. (F) Fraction newly synthesized CoQ in 13 
KPC cells in vehicle control (DMSO) and simvastatin treated cells after 48 h. (G) 14 
CoQ pool size in KPC cells treated with simvastatin for 48 h. Values are relative to 15 
control. All data shown as mean ± SEM of (B) 2 (C) 4, (D-G) 3 biological replicates, 16 
each performed in triplicate. Statistical significance was tested by ANOVA (C) and t-17 
test (F) and (G). ****p<0.0001, **: p<0.01 Abbreviations: ns- non-significant. See also 18 
Figure S1. 19 
 20 
Figure 2. Diminished CoQ levels lead to succinate accumulation, reduced 21 
oxidative phosphorylation, and increased glycolysis 22 
(A) Effect of statins on succinate pool sizes in KPC, MIA-PaCa2 and PC3 cells. Peak 23 
areas were normalized to cell number and shown relative to vehicle control (DMSO). 24 
(B) Effect of statin treatment on oxidative phosphorylation. Cells were pre-treated 25 
with vehicle control (DMSO) or simvastatin for 24 h prior to analysis. (C) Glucose 1 
uptake and lactate release rates in the media quantified after 48 h of simvastatin 2 
treatment. All data shown as mean ± SEM of (A) 3 or 1 (C) representative biological 3 
replicates, each experiment performed in triplicate, (B) 3 biological replicates each 4 
with 10 replicates. Abbreviations: OCR: Oxygen consumption rate, Rot/AA: rotenone 5 
and antimycin A. Statistical significance was tested by t-test. *: p<0.05, **: p<0.01 6 
and ****p<0.0001. See also Figure S2.  7 
 8 
Figure 3. Statin treatment causes increased redox stress and metabolic 9 
compensation. 10 
(A) Effect of simvastatin (Simva) on the ratio of oxidized (GSSG) to reduced (GSH) 11 
glutathione (48 h). Relative to vehicle control (DMSO). (B) Overview of metabolic 12 
pathways mitigating oxidative stress. (C) Glutamine uptake and glutamate release 13 
rates in response to vehicle or simvastatin (2 µM). (D) Citrate labeling from [U13C]-14 
glutamine tracing for 48 h. (E) Change in cystine uptake in response to simvastatin 15 
treatment. Rates are relative to vehicle control.  (F) Effect of simvastatin treatment 16 
on intracellular cystine levels (48 h). Values are relative to control. (G) qPCR 17 
analysis of xCT following statin treatment and statin plus mevalonolactone (Mev.)  18 
(48 h). (H) Proline labeling from [U13C]-glutamine after statin treatment (48 h). Peak 19 
areas were normalized to cell number and expressed relative to control. (I) qPCR 20 
analysis of PYCR1 after simvastatin treatment and statin plus mevalonolactone 21 
(Mev.)   (48 h). (J) Intracellular hydroxyproline levels in response to statin treatment. 22 
Peak areas were normalized to cell numbers and expressed relative to control. All 23 
data shown as mean ± SEM of  (A), (D), (F), (J) 3 biological replicates, each 24 
performed in triplicate, (C), (E), (H) 1 representative biological replicate, each 25 
performed in triplicate, (G), (I) 3 biological replicates from 6 technical repeats.  1 
Statistical significance was tested by ANOVA for (G) and (I), rest by t-test. *: p<0.05, 2 
**: p<0.01, ***: p<0.001, ****p<0.0001. See also Figure S3. 3 
 4 
Figure 4. Statin treated KPC mice have reduced tumor CoQ synthesis and 5 
pronounced oxidative stress.  6 
(A) Fraction newly synthesized CoQ9 in KPC PDAC tumors and benign adjacent 7 
pancreas. (B) Immunohistochemistry (IHC) and scoring of DNA damage response by 8 
ɣH2AX in tumor. Scale bar in larger image represents 50 µm, smaller image 9 
represents 20 µm. (C) qPCR analysis of xCT in PDAC tumors from KPC mice. For 10 
(A), (C) data shown as mean ± SEM for n = 4 mice per group. Note one vehicle 11 
mouse had no benign pancreas. For (B) quantification shown as median score ± 12 
SEM from 30 frames for n = 4 mice per group. Abbreviations: Panc: Pancreas, Veh: 13 
Vehicle. Statistical significance was tested by student’s t-test for (A), (C) and Mann-14 
Whitney (B). *:p<0.05, **: p<0.01 and ****p<0.0001. See also Figure S4. 15 
 16 
Figure 5. A MEK inhibitor (AZD6244) synergizes with statin treatment to induce 17 
 cell death due to excessive ROS.  18 
(A) qPCR analysis of xCT expression following 48 h treatment with simvastatin, 19 
AZD6244 or combination. (B) Intracellular ROS as measured by DCFDA assay after 20 
24 h treatment with simvastatin, AZD6244 or a combination. (C) Cell numbers 21 
following 96 h exposure to indicated conditions. Numbers are relative to vehicle 22 
(DMSO) treated control. (D) qPCR analysis of xCT (Slc7a11) expression in KPC 23 
PDAC tumors. (E) Schematic to show AZD6244 action reducing xCT level. (F) 24 
Caspase-3 IHC and scoring of KPC mice treated with vehicle control, simvastatin, 25 
AZD6244 or AZD6244 + simvastatin.  (G) H&E IHC and scoring of apoptotic bodies 1 
in KPC mice treated as in (F). Arrows indicate apoptotic bodies. For images, scale 2 
bar in larger image represents 50 µm, smaller image represents 20 µm. Data shown 3 
as mean ± SEM of  (A) 3 biological replicates with each 6 technical replicates,  (B) 3 4 
biological replicates, with each 8 technical replicates, (C) 3 biological replicates, 5 
each performed in triplicate, (D), (F), (G) data is shown for n = 4 mice per group. (F), 6 
(G) quantification shown as median score ± SEM from 20 frames.  Statistical 7 
significance was tested by ANOVA for (A), (B), (C), (D) or Mann-Whitney for (F), (G). 8 
*: p<0.05, **: p<0.01, ***: p<0.001, ****p<0.0001. See also Figure S5. 9 
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